Advertisement for orthosearch.org.uk
Results 1 - 7 of 7
Results per page:
Orthopaedic Proceedings
Vol. 106-B, Issue SUPP_19 | Pages 78 - 78
22 Nov 2024
Lutro O Tjørhom MB Fenstad AM Leta TH Hallan G Bruun T Furnes O Gjertsen J Dale H
Full Access

Aim

The current recommendation in Norway is to use four doses of a first-generation cephalosporin (cefazolin or cephalotin) as systemic antibiotic prophylaxis (SAP) the day of surgery in primary joint arthroplasty. Due to shortage of supply, scientific development, changed courses of treatment and improved antibiotic stewardship, this recommendation has been disputed. We therefore wanted to assess if one dose of SAP was non-inferior to four doses in preventing periprosthetic joint infection (PJI) in primary joint arthroplasty.

Method

We included patients with primary hip- and knee arthroplasties from the Norwegian Arthroplasty Register and the Norwegian Hip Fracture Register for the period 2005-2023. We included the most used SAPs (cephalotin, cefazolin, cefuroxime, cloxacillin and clindamycin), administered as the only SAP in 1-4 doses, starting preoperatively. Risk of revision (Hazard rate ratio; HRR) for PJI was estimated by Cox regression analyses with adjustment for sex, age, ASA class, duration of surgery, reason for- and type of arthroplasty, and year of primary arthroplasty. The outcome was 1-year reoperation or revision for PJI. Non-inferiority margins were calculated for 1, 2 and 3 doses versus reference of 4 doses of SAP at the day of surgery, against a predetermined limit of 15% increased risk of PJI.


Orthopaedic Proceedings
Vol. 106-B, Issue SUPP_19 | Pages 16 - 16
22 Nov 2024
Høvding P Hallan G Furnes O Dale H
Full Access

Background and purpose

Previous publications have reported an increased but levelling out risk of revision for infection after total hip arthroplasty (THA) in Norway. We assessed the changes in risk of major (cup and/or stem, 1- or 2-stage) and minor revisions (debridement, exchange of modular parts, antibiotics and implant retention (DAIR)) for infection after primary THAs reported to the Norwegian Arthroplasty Register (NAR) over the period 2005-2022.

Patients and methods

Primary THAs reported to the NAR from 2005 to 2022 were included. Time was stratified into time periods (2005-2009, 2010-2018, 2019-2022) based on a previous publication. Cox regression analyses, adjusted for sex, age and ASA-classification, with the first revision for infection were performed.


Orthopaedic Proceedings
Vol. 104-B, Issue SUPP_10 | Pages 67 - 67
1 Oct 2022
Dale H Fenstad AM Hallan G Overgaard S Pedersen AB Hailer NP Kärrholm J Rolfson O Eskelinen A Mäkelä K Furnes O
Full Access

Aim

Previous publications have suggested that the incidence of revisions due to infection after THA is increasing. We performed updated time-trend analyses of risk and timing of revision due to infection after primary THAs in the Nordic countries during the period 2004–2018.

Methods

569,463 primary THAs reported to the Nordic Arthroplasty Register Association from 2004 through 2018 were studied. We estimated adjusted hazard ratios (aHR) with 95% confidence interval by Cox regression with the first revision due to infection after primary THA as endpoint. The risk of revision was investigated. In addition, we explored changes in the time span from primary THA to revision due to infection.


Orthopaedic Proceedings
Vol. 104-B, Issue SUPP_10 | Pages 37 - 37
1 Oct 2022
Lutro O Mo S Leta TH Fenstad AM Tjørhom MB Bruun T Hallan G Furnes O Dale H
Full Access

Aim

In recent years, many studies on revision for infection after arthroplasty have been published. In national arthroplasty registers, revision for infection is defined as surgical debridement, with or without removal or exchange of the entire or parts of the prosthesis due to deep infection, and should be reported to the register immediately after surgery. The diagnosis of infection is made at the surgeon's discretion, based on pre- and perioperative assessment and evaluation, and is not to be corrected to the register based on peroperative bacterial cultures. Due to this lack of validation, the rate of revision for infection will only be an approximation of the true rate of periprosthetic joint infection (PJI). Our aim was to validate the reporting of infection after total hip arthroplasty, and to assess if revisions for infection actually represented true PJI.

Methods

We investigated the reported revisions for infection and aseptic loosening after total hip arthroplasty from 12 hospitals, representing one region of the country, reported during the period 2010–2020. The electronic patient charts were investigated for information on surgical treatment, use of antibiotics, biochemistry and microbiology findings. PJI was defined as growth of at least two phenotypically identical microbes in perioperative tissue samples. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy were calculated.


Orthopaedic Proceedings
Vol. 101-B, Issue SUPP_14 | Pages 90 - 90
1 Dec 2019
Langvatn H Schrama JC Engesæter LB Hallan G Furnes O Lingaas E Walenkamp G Dale H
Full Access

Aim

The aim of this study was to assess the influence of the true operating room (OR) ventilation on the risk of revision due to infection after primary total hip arthroplasty (THA) reported to the Norwegian Arthroplasty Register (NAR).

Method

40 orthopedic units were included during the period 2005 – 2015. The Unidirectional airflow (UDAF) systems were subdivided into small-area, low-volume, vertical UDAF (lvUDAF) (volume flow rate (VFR) (m3/hour) <=10,000 and diffuser array size (DAS) (m2) <=10); large-area, high-volume, vertical UDAF (hvUDAF) (VFR >=10,000 and DAS >=10) and Horizontal UDAF (H-UDAF). The systems were compared to conventional, turbulent ventilation (CV) systems. The association between revision due to infection and OR ventilation was assessed using Cox regression models, with adjustments for sex, age, indication for surgery, ASA-classification, method of fixation, modularity of the components, duration of surgery, in addition to year of primary THA. All included THAs received systemic, antibiotic prophylaxis.


Orthopaedic Proceedings
Vol. 100-B, Issue SUPP_17 | Pages 19 - 19
1 Dec 2018
Leta TH Lygre SHL Høvding P Schrama J Hallan G Dale H Furnes O
Full Access

Background

Periprosthetic joint infection (PJI) after knee arthroplasty surgery remains a serious complication. Yet, there is no international consensus on the surgical treatment of PJI. The purpose was to assess the prosthesis survival rates, risk of re-revision, and mortality rate following the different surgical strategies (1-stage or 2-stage implant revision, and irrigation and debridement (IAD) with implant retention) used to treat PJI.

Methods

The study was based on 653 total knee arthroplasties (TKAs) revised due to PJI in the period 1994 to 2016. Kaplan-Meier (KM) and multiple Cox regression analyses were performed to assess the survival rate of these revisions and the risk of re-revisions. We also studied the mortality rates at 90 days and 1 year after revision for PJI.


Orthopaedic Proceedings
Vol. 98-B, Issue SUPP_23 | Pages 50 - 50
1 Dec 2016
Lutro O Dale H Sjursen H Schrama JC Høvding P Bartz-Johannessen CA Hallan G Engesæter LB
Full Access

Aim

To see what surgical strategy was used in treating infected total hip arthroplasties (THA), relative to bacterial findings, level of inflammation, length of antibiotic treatment (AB) and re-revisions. Further, to assess the results of treatment after three months and one year.

Method

We used our national arthroplasty register (NAR) to identify THA revised for deep infection from 2004–2015 reported from our hospital. We identified the strategy of revision, i.e. one-stage exchange (one-stage), two-stage exchange (two-stage), debridement and implant retention (DAIR), or Girdlestone, and reported re-revisions for infection. We defined cure as no AB, no need for further surgery and joint with prosthesis (not Girdlestone).

From the hospitals’ medical records we retrieved bacterial findings from the revisions, level of C-reactive protein (CRP), type of antibiotics given, duration of antibiotic therapy and clinical data regarding the patients. The information reported to the NAR was also validated.